In HNSCC, it is essential to note that a crucial prerequisite for the use of PD-L1/PD-1 inhibitors in immunotherapy is the integrity of MHC-I APM and the substantial activation of MHC-I.252. Here, PDCD1 is linked to head and neck squamous cell carcinoma.